Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15660301 | 1.00 | NAAA (0.63) | NAAAL3MBTL1HDAC3PPARGPPARA | |
| SCHEMBL15677528 | 1.00 | NAAA (0.63) | NAAAL3MBTL1HDAC3PPARGPPARA | |
| SCHEMBL15657782 | 1.00 | NAAA (0.63) | NAAAL3MBTL1HDAC3PPARGPPARA | |
| SCHEMBL15677537 | 0.86 | ELANE (0.54) | NAAAHDAC3EPHX1 | |
| SCHEMBL15677534 | 0.86 | ELANE (0.54) | NAAAHDAC3EPHX1 | |
| SCHEMBL15660413 | 0.85 | NAAA (0.63) | NAAAL3MBTL1HDAC3ALDH1A1EPHX1 | |
| SCHEMBL15660841 | 0.85 | NAAA (0.63) | NAAAL3MBTL1HDAC3ALDH1A1EPHX1 | |
| SCHEMBL15660391 | 0.81 | HDAC1 (0.57) | NAAAL3MBTL1HDAC3ALDH1A1HTT | |
| SCHEMBL16421901 | 0.81 | HDAC1 (0.57) | NAAAL3MBTL1HDAC3ALDH1A1HTT | |
| SCHEMBL15662096 | 0.81 | ALDH1A1 (0.56) | NAAAHDAC3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150031892-A1 | SPHINGOLIPID METABOLITE MIMETICS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-01-29 | — | — | US | claimed |
| WO-2014066613-A2 | SPHINGOLIPID METABOLITE MIMETICS | ZHEJIANG UNIVERSITY (CN) | 2014-05-01 | — | — | WO | claimed |
| US-20150031892-A1 | SPHINGOLIPID METABOLITE MIMETICS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-01-29 | — | — | US | disclosed |
| US-20150031892-A1 | SPHINGOLIPID METABOLITE MIMETICS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-01-29 | — | — | US | disclosed |
| WO-2014066613-A2 | SPHINGOLIPID METABOLITE MIMETICS | ZHEJIANG UNIVERSITY (CN) | 2014-05-01 | — | — | WO | disclosed |
| WO-2014066613-A2 | SPHINGOLIPID METABOLITE MIMETICS | ZHEJIANG UNIVERSITY (CN) | 2014-05-01 | — | — | WO | disclosed |
| US-20110105603-A1 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES | AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC. (US) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105603-A1 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES | APP, BACE1, PTMS | NAAA 1846/4885L3MBTL1 369/4885HDAC3 4844/4885 |
| US-20150031892-A1 | SPHINGOLIPID METABOLITE MIMETICS | BID, BAD, S1PR1 | NAAA 1366/4885L3MBTL1 1216/4885HDAC3 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.